07:00 , May 28, 2015 |  BC Innovations  |  Targets & Mechanisms

Joint attack

A newly discovered pathway that causes joint erosion in rheumatoid arthritis could lead to a new class of therapies that act locally in cells of the synovial lining and avoid the drawbacks of immunosuppressants. The...
07:00 , Oct 8, 2007 |  BC Week In Review  |  Company News

Bradmer management update

Bradmer Pharmaceuticals Inc. (TSX:BMR), Toronto, Ontario   Business: Cancer   Hired: Zafeer Ahmad as VP of manufacturing operations, formerly VP of process development and manufacturing at NeoPharm Inc.   Resigned: Kerry Barnhart as president and...
07:00 , Aug 13, 2007 |  BC Week In Review  |  Company News

Bradmer management update

Bradmer Pharmaceuticals Inc. (TSX:BMR), Toronto, Ontario   Business: Cancer   Promoted: Brian Brohman to chief business officer, while remaining CFO; and Alan Ezrin to CEO from COO; Ezrin replaces Mark Rogers, who will become executive...
08:00 , Feb 26, 2007 |  BC Week In Review  |  Company News

Cardiome management update

Cardiome Pharma Corp. (TSX:COM; CRME), Vancouver, B.C.   Business: Cardiovascular   Promoted: Don McAfee to CSO from VP of research; he replaces acting CSO Alan Ezrin   Hired: Karim Lalji as SVP of commercial affairs,...
08:00 , Feb 20, 2001 |  BC Week In Review  |  Company News

Nortran management update

Nortran Pharmaceuticals Inc. (VSE:NRT; NTRDF), Vancouver, B.C.   Business: Cardiovascular, Neurological, Pulmonary   Hired: Alan Ezrin as CSO and a director, formerly CSO at ConjuChem Inc.  ...
07:00 , Jul 14, 1997 |  BioCentury  |  Emerging Company Profile

RedCell Canada Inc.

RedCell Canada Inc. Montreal, Quebec Technology: Bioconjugation and drug delivery using site-specific affinity probes for plasma proteins or membrane proteins in red blood cells Disease focus: Deep vein thrombosis, pain and cancer Clinical status: Preclinical...
07:00 , Jul 14, 1997 |  BioCentury  |  Emerging Company Profile

RedCell: Permanent bonds

Emerging Company Profile RedCell: Permanent bonds Many drugs fail in development because they are rapidly metabolized or cleared from the body too rapidly to have a therapeutic effect. Others must be given at such high...
07:00 , Jun 9, 1997 |  BC Week In Review  |  Company News

RedCell management update

(RedCell closes first tranche of private placement, B15) RedCell Canada Inc., Montreal, Quebec   Business: Drug delivery   Promoted: Alan Ezrin, Ph.D., to president and acting CEO; formerly VP of preclinical development  ...